RT Journal Article
SR Electronic
T1 Nilotinib in Patients with Advanced Parkinson’s Disease: A Randomized Phase 2A Study (NILO-PD)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.11.20093146
DO 10.1101/2020.05.11.20093146
A1 Simuni, Tanya
A1 Fiske, Brian
A1 Merchant, Kalpana
A1 Coffey, Christopher S.
A1 Klingner, Elizabeth
A1 Caspell-Garcia, Chelsea
A1 Lafontant, David-Erick
A1 Matthews, Helen
A1 Wyse, Richard K.
A1 Brundin, Patrik
A1 Simon, David K.
A1 Schwarzschild, Michael
A1 Weiner, David
A1 Adams, Jaime
A1 Venuto, Charles
A1 Dawson, Ted M.
A1 Baker, Liana
A1 Kostrzebski, Melissa
A1 Ward, Tina
A1 Rafaloff, Gary
YR 2020
UL http://medrxiv.org/content/early/2020/05/12/2020.05.11.20093146.abstract
AB Background Nilotinib, a tyrosine kinase Abelson inhibitor, exhibits neuroprotective effects in preclinical Parkinson disease (PD) models.Methods This Phase 2A double-blind placebo-controlled study in moderate/advanced PD randomized participants 1:1:1 to placebo:150:300 mg nilotinib in matching capsules once daily for 6 months. The primary outcomes were safety and tolerability, the latter defined as ability to complete the study on assigned dose. Secondary outcomes included change in PD disability (Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), Part 3 OFF/ON). Additional exploratory outcomes included serum and cerebrospinal fluid (CSF) pharmacokinetic (PK) profile, and CSF dopamine metabolites.Findings The study screened 125 and enrolled 76 participants (39% screen failure) between November 2017 and December 2018 at 25 US sites. The last participant completed the study in September 2019. At baseline, mean (standard deviation) age was 64.6 years (7.5), disease duration 9.9 years (4.7), MDS-UPDRS Part 1-3 OFF score 66.4(19.3) and ON score 48.4(16.2), Montreal Cognitive Assessment (MoCA) score 27.1(2.2). Tolerability was 21(84%):19 (76%):20 (77%) in placebo:150:300 mg arm, respectively. Both active doses were safe. The most common reasons for drug suspension were elevations of amylase and/or lipase, which were dose-dependent. The 300 mg group had transitory worsening of MDS-UPDRS-3 ON at 1 month compared to placebo (p<0.01), which resolved by 6 months. There was no difference in the change of MDS-UPDRS-3 OFF from baseline to 6 months between the groups (p=0.17). CSF/serum PK ratio was 0.2-0.3%. There was no evidence of treatment-related elevation of any dopamine metabolites.Interpretation Both doses of nilotinib were safe and tolerable in these participants, who were selected with strict inclusion/exclusion criteria. There was no evidence of any symptomatic benefit of nilotinib. The drug had low CSF exposure and failed to change dopamine metabolites. These findings do not warrant further testing of nilotinib in PD.Funding The study was funded by Funded by Michael J Fox Foundation for Parkinson’s Research / The Cure Parkinson Trust / Van Andel Institute. Clinicaltrials.gov NCT03205488Competing Interest StatementLiana Baker, Dr. David-Erick Lafontant, Elizabeth Klingner, Dr. Gary Rafaloff, Helen Matthews, Dr. Jaime Adams, Melissa Kostrzebski, Dr. Richard Wyse, Dr. Chelsea Caspell-Garcia and Ms.Tina Ward have nothing to disclose. Dr. Tanya Simuni reports grants from NINDS, MJFF, Parkinson’s Foundation, grants from Biogen, Roche, Neuroderm, Sanofi, Sun Pharma, Abbvie, IMPAX, Prevail, other from Acadia, Abbvie, Accorda, Adamas, Allergan,Amneal, Aptinyx, Denali, General Electric (GE), Kyowa, Neuroderm, Neurocrine, Sanofi, Sinopia, Sunovion, Roche, Takeda, Voyager, US World Meds, during the conduct of the study. Dr. Charles Venuto reports personal fees and non-financial support from Michael J Fox Foundation via Northwestern University, during the conduct of the study; grants from Michael J. Fox Foundation, outside the submitted work. Dr. David Simon reports personal fees from Michael J Fox Foundation, during the conduct of the study; personal fees from Biogen, grants and personal fees from Lysosomal Therapeutics, Inc., grants from Voyager Therapeutics, personal fees from Halloran Consulting Group, personal fees from Chase Therapeutics, grants from BioElectron Technology, grants from Neuraly, outside the submitted work. Dr. David Weiner is an advisor to the Michael J Fox Foundation. Dr. Kalpana Merchant reports personal fees from Vincere Biosciences, personal fees from Sinopia Biosciences, grants and personal fees from Michael J Fox Foundation, personal fees from TransThera Consulting Co., other from Eli Lilly and Co., outside the submitted work. Dr. Ted Dawson reports grants from MJFF, grants from NIH/NINDS, during the conduct of the study; grants and personal fees from Sun Pharma Advanced Research Company, personal fees from Inhibikase Therapeutics, Inc., personal fees from Neuraly, Inc., grants, personal fees and non-financial support from Valted Seq Inc., outside the submitted work; In addition, Dr. Dawson has a patent BIOMARKERS FOR NEURODEGENERATIVE DISORDERS pending. Dr. Patrik Brundin reports other from Axial Biotherapeutics, personal fees from CuraSen, personal fees from Fujifilm-Cellular Dynamics International, personal fees from IOS Press Partners, personal fees from LifeSci Capital LLC, grants and personal fees from Lundbeck A/S, personal fees from Living Cell Technologies LTD, grants from Roche, other from Acousort AB, other from Gilead, other from Moderna Inc, other from Inovia outside the submitted work. Dr. Michael Schwarzschild reports personal fees from Michael J. Fox Foundation for Parkinson’s Research, during the conduct of the study; personal fees from Prevail Therapeutics, personal fees from Eli Lilly and Co., other from Acorda Therapeutics, non-financial support from Denali, personal fees from nQ Medical, outside the submitted work. Clinical TrialNCT03205488Funding StatementThe study was funded by Funded by Michael J Fox Foundation for Parkinson’s Research / The Cure Parkinson Trust / Van Andel Institute. Clinicaltrials.gov NCT03205488Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailable